RIGHT OF FIRST REFUSAL
ANDCO-SALE AGREEMENT
THIS RIGHT OF FIRST REFUSAL ANDCO-SALE AGREEMENT (this “Agreement”), is made as of the 30 day of April, 2018 by and among Inhibrx, Inc., a Delaware corporation formerly known as Tenium Therapeutics, Inc. (the “Company”), the Investors (as defined below) listed onSchedule A and the Key Holders (as defined below) listed onSchedule B.
WHEREAS, in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of April 30, 2018, by and among certain Target Parties (as defined therein) and the Company (the “Merger Agreement”), certain Investors received shares of Preferred Stock (as defined below) of the Company, set forth opposite the name of such Investors onSchedule A, and certain Key Holders became the beneficial owner of the number of shares of Capital Stock set forth opposite the name of such Key Holder onSchedule B;
WHEREAS,in connection with the consummation of the transactions contemplated by that certain Exchange Agreement, dated as of April 30, 2018, by and among the Members (as defined therein) and the Company (the “Exchange Agreement”), certain Investors received shares of Preferred Stock set forth apposite the name of such Investors onSchedule A and certain Key Holders became the beneficial owner of the number of shares of Capital Stock set forth opposite the name of such Key Holder onSchedule B;
WHEREAS, the Company anticipates entering into a Series Mezzanine 2 Preferred Stock Purchase Agreement with certain parties that will become party to this Agreement (the “Future Purchasers”) on such date and with such terms as are to be determined by the Company (the “Purchase Agreement”); and
WHEREAS, the Key Holders and the Company desire to further induce certain of the Investors to approve the Merger Agreement and the Exchange Agreement and the Future Purchasers to purchase the Preferred Stock pursuant to the Purchase Agreement.
NOW, THEREFORE, the Company, the Key Holders and the Investors agree as follows:
1. Definitions.
1.1 “Affiliate” means, with respect to any specified Investor, any other Investor who directly or indirectly, controls, is controlled by or is under common control with such Investor, including, without limitation, any general partner, managing member, officer, director or trustee of such Investor, or any venture capital fund or registered investment company now or hereafter existing which is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Investor.
1.2 “Board of Directors” means the board of directors of the Company.
1.3 “Capital Stock” means (a) shares of Common Stock, Series Mezzanine 1 Preferred Stock (whether now outstanding or hereafter issued in any context) and Series Mezzanine 2 Preferred Stock (whether now outstanding or hereafter issued in any context) (collectively, the “Preferred Stock”), (b) shares of Common Stock issued or issuable upon
1